GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Bausch & Lomb (Bausch & Lomb) Total Revenue Growth Rate (Future 3Y To 5Y Est) : 7.10 (As of May. 14, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est) is 7.10.

Competitive Comparison of Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Bausch & Lomb  (NYSE:BLCO) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Bausch & Lomb Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (Bausch & Lomb) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
TSX:OPS TSXV:ZEN TSXV:OTC XCNQ:TEVO ISRG XPAR:EL BDX TSE:7741 XSWX:ALC WST OCSE:COLO B RMD TSE:4543 XSWX:STMN XPAR:DIM BAX TSE:7733 HOLX COO TSE:6869
Traded in Other Exchanges
S2L:Germany BLCO:Canada
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Website
https://www.bausch.com
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Executives
Luc Bonnefoy officer: President,Surgical C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Andrew J. Stewart officer: See remarks C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Bailey A Robert D officer: EVP & Chief Legal Officer C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Brent L Saunders director, officer: CEO and Chair 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Gaoxiang Hu director 16690 COLLINS AVE., SUITE PH-1, SUNNY ISLES BEACH FL 33160
Bausch Health Companies Inc. 10 percent owner 2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC A8 H7L 4A8
Sarah B Kavanagh director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Nathalie D. Bernier director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Yehia Hashad officer: EVP, R&D and CMO C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Ross Thomas W. Sr. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Russel C Robertson director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807